Xuebiao Yao to Antineoplastic Agents
This is a "connection" page, showing publications Xuebiao Yao has written about Antineoplastic Agents.
Connection Strength
0.295
-
Fang C, Li W, Yin R, Zhu D, Liu X, Wu H, Wang Q, Wang W, Bai Q, Chen B, Yao X, Chen Y. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway. Sci Rep. 2021 08 13; 11(1):16507.
Score: 0.116
-
Wang F, Wang LS, Gao YH, Yao XD. VHL enhances 9-cis-retinoic acid treatment by down-regulating retinoid X receptor a in renal cell carcinomas. Biochem Biophys Res Commun. 2020 03 05; 523(2):535-541.
Score: 0.104
-
Zhang HL, Zhu Y, Wang CF, Yao XD, Zhang SL, Dai B, Shen YJ, Zhu YP, Shi GH, Ye DW. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. Int J Urol. 2011 Jun; 18(6):422-30.
Score: 0.057
-
Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y, Fan D. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6239-47.
Score: 0.009
-
Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003 Jun 20; 278(25):23130-40.
Score: 0.008